Armata Pharmaceuticals (ARMP) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Humacyte (HUMA) over the past year, gaining 21.3% versus a loss of 71.3%. Over five years, ARMP leads with a +10.4% price change compared with -95.4% for HUMA. Armata Pharmaceuticals is the larger company by market cap ($141.7 million vs $131.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | HUMA |
|---|---|---|
| Share price | $3.81 | $0.4723 |
| Market cap | $141.66M | $131.20M |
| 1-day change | -1.04% | -1.19% |
| YTD return | -39.33% | -50.85% |
| 1-year return | +21.34% | -71.29% |
| 5-year return | +10.43% | -95.38% |
| EPS (TTM) | $-5.29 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $1.90 |
| 52-week low | $3.09 | $0.46 |
| Distance from 52-week high | -76.68% | -75.08% |
| Average volume | 211.49K | 6.35M |
| Shares outstanding | 37.18M | 277.80M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed HUMA by 92.6 percentage points over the past year.
ARMP vs HUMA FAQ
Which is bigger, Armata Pharmaceuticals or Humacyte?
Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $141.66M compared with $131.20M for Humacyte (HUMA).
Which stock has performed better over the past year, ARMP or HUMA?
ARMP returned +21.34% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.